Antitumoral action of rosiglitazone. in vivo and in vitro studies.

NÚÑEZ M; MARTIN G; COCCA C; GUTIERREZ A; CROCI M; CRESCENTI E; CRICCO G; MOHAMAD N; MEDINA V; RIVERA E; BERGOC R

Corfu, Grecia

Congreso; 7th International Conference of Anticancer Research; 2004

Thiazolidinediones are widely used for treatment of type 2 diabetes mellitus. Peroxisome proliferator activated receptors (PPARs) are  members of the nuclear hormone receptor superfamily. PPARg is of  particular interest because it is (has been) implicated in several human pathological situations, including diabetes and cancer. Current studies looking for more effective treatments, point out thiazolidinediones (e.g. rosiglitazone (Rosi)) as possible antitumoral agents. Current studies propose*/indicate a possible role of thiazolidinediones (e.g. rosiglitazone (Rosi)) as antitumoral agents. The aim of our investigation was to study the action of Rosi in comparison with the antiestrogen tamoxifen (Tam). In vivo and in vitro studies were performed. We evaluated the effect of Rosi (0,06 mg/kg/day) and Tam (1mg/kg/day) on rats bearing mammary tumors induced by three ip doses of the carcinogen N-Nitroso-N-Metilurea. Rats basal glicemia, insulin levels and glucose tolerance test were not modified by Rosi treatment. The results obtained showed that Rosi treatment produces the growth inhibition of 45% of the tumors vs 55% of regression produced by Tam (P